Chronic beta-adrenergic stimulation increases in mice the sensitivity to methysergide and the number of cerebral high affinity serotonin binding sites (5-HT-1)
| Autor: | H. Frances, C. Bulach, M. Fillion, Pierre Simon, G. Fillion |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Male
Agonist Serotonin medicine.medical_specialty Reserpine medicine.drug_class Methysergide Pharmacology Mice Internal medicine Receptors Adrenergic beta medicine Animals Clenbuterol Biological Psychiatry 5-HT receptor Binding Sites Movement Disorders Chemistry Brain Drug Synergism Long-term potentiation Psychiatry and Mental health Endocrinology Serotonin binding Neurology Ethanolamines Neurology (clinical) medicine.drug |
| Zdroj: | Journal of Neural Transmission. 67:215-224 |
| ISSN: | 1435-1463 0300-9564 |
| DOI: | 10.1007/bf01243349 |
| Popis: | Reserpine administration in mice causes, among other effects an akinesia which can be reversed by the serotonin agonist-antagonist methysergide. The effect of methysergide is potentiated by clenbuterol, a beta-adrenergic agonist, which itself causes hypomotility. Potentiation is weak after a single injection of clenbuterol, but becomes much stronger after repeated administration for 12 days. This treatment also causes a 50% increase in the number of high affinity 5-HT-1 binding sites in the brain. This increase would explain the increased potency of methysergide against reserpine-induced akinesia. These results show that: a beta-adrenergic drug, clenbuterol modulates the serotoninergic system; this modulation takes its importance after chronic treatment only; this interrelation may be important in depressive illness since it is observed on a test used in the screening of antidepressant drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink